The PFS rate of DE-DLBCL patients treated with ZR-CHOP was higher than that of R-CHOP, even though the difference was not significant (3-year PFS rates: 77.5% vs. 47.6%, P= 0.072). The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.